AbbVie Inc ABBV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
AbbVie Gets FDA OK of Juvmo for Parkinson's Disease
-
ADARx Pharmaceuticals to Sell 21.9 Million Shares at $15-$17 Each in IPO
-
AbbVie's Menstrual Migraine Treatment Meets Primary, Secondary Endpoints in Phase 3 Trial
-
Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze.
-
AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study
-
Moderna's cancer-vaccine breakthrough drives broad biopharma stock rally
-
AbbVie Lowers Outlook to Account for Acquisition, as 2Q Profit Jumps
-
AbbVie Gets Europe OK for Rinvoq in Vitiligo, Alopecia Areata
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 1.77B
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 24.82
- Price/Sales
- 7.43
- Dividend Yield (Trailing)
- 2.53%
- Dividend Yield (Forward)
- 2.66%
- Dividend Payment Schedule
- Feb, May, Aug, Nov
- Total Yield
- 2.84%
Company Profile
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 57,000
- Website
- https://www.abbvie.com
Competitors
Valuation
|
Metric
|
ABBV
|
MRK
|
LLY
|
|---|---|---|---|
Price/Earnings (Normalized) | 24.82 | 44.80 | 36.51 |
Price/Book Value | — | 8.47 | 30.26 |
Price/Sales | 7.43 | 5.36 | 12.94 |
Price/Cash Flow | 20.48 | 16.10 | 31.35 |
Price/Earnings
ABBV
MRK
LLY
Financial Strength
|
Metric
|
ABBV
|
MRK
|
LLY
|
|---|---|---|---|
Quick Ratio | 0.49 | 0.71 | 0.68 |
Current Ratio | 0.81 | 1.32 | 1.35 |
Interest Coverage | 3.89 | 4.28 | — |
Quick Ratio
ABBV
MRK
LLY
Profitability
|
Metric
|
ABBV
|
MRK
|
LLY
|
|---|---|---|---|
Return on Assets (Normalized) | 14.29% | 6.27% | 24.05% |
Return on Equity (Normalized) | — | 16.68% | 105.62% |
Return on Invested Capital (Normalized) | 32.02% | 9.82% | 39.55% |
Return on Assets
ABBV
MRK
LLY
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|@!@ytF&? | LOCK|xWz | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|h><ngb | LOCK|$hF | $617B | |||
| AbbVie Inc
ABBV
| LOCK|&RrB^?T | LOCK|Crw | $464B | |||
| Merck & Co Inc
MRK
| LOCK|x>B!l# | LOCK|T$ | $356B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|RHr#%%< | LOCK|jp | $333B | |||
| Novartis AG ADR
NVS
| LOCK|WBjLtBH! | LOCK|Pg | $266B | |||
| AstraZeneca PLC
AZN
| LOCK|TC>PM%?! | LOCK|Z^F | $243B | |||
| Amgen Inc
AMGN
| LOCK|cK^cvmZ | LOCK|!h% | $218B | |||
| Gilead Sciences Inc
GILD
| LOCK|G&%W%v$ | LOCK|$& | $179B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|Nb>&<Bz | LOCK|<J | $165B |
United States